This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation smallmolecules. However, the advanced nature of the drugs being developed has brought new challenges. The global market for CNS therapeutics was worth an estimated $144.3
PK Intravenous Dosing: Exponential Decay Equation Intravenous (IV) dosing refers to the administration of a drug directly into the bloodstream by injection (bolus) or continuous infusion. This approach is essential for understanding drug absorption, distribution, metabolism, and elimination (ADME).
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.
In some cases, industry will recognize a novel insight emerging from the Broad and successfully launch a drug discovery project; more often, biological discoveries require additional work to move them to a point where industry is willing and able to ‘take over’.
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Given the full potential of future assets can’t be directly observed or measured, drug developers are often unaware of certain opportunities or risks.
G protein-coupled receptors (GPCRs) are a highly validated drug target family – accounting for 30-35 percent of all approved drugs. Despite this, the therapeutic potential of targeting most GPCRs remains untapped, as only 10 percent of GPCRs have been drugged.
Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.
Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology.
Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in smallmoleculedrug discovery. Data sharing without compromise Drug discovery has long been characterised by a strong culture of secrecy.
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.
Altasciences At CPHI Americas 2025 pmjackson Thu, 07/03/2025 - 13:41 In the ever-changing drug development world, staying agile is essential to enabling more informed decisions, faster. It’s a challenge that affects a large percentage of new drug candidates—one we’re passionate about helping to solve. Why does that matter?
As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted smallmolecules aimed at revolutionising cancer treatment. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. The addition of Drug Product assets for cytotoxic substances completes the fully integrated offering.
Magazine ENEWS SUBSCRIBE WEBINARS PODCASTS EBOOKS ABOUT US Edit submissions Media kit Innovation Awards Articles Flow state: The evolving shape of continuous manufacturing June 17, 2025 While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.
Domain Therapeutics is addressing this challenge by focusing on G protein-coupled receptors (GPCRs) – a well-validated and the largest family of drug targets that remains underexplored in cancer and inflammation. Targeting PAR2 is not simple, and its structural complexity and unique biology have made the receptor difficult to drug.
Unlike most approved drugs, which work by turning cell signaling up or down like a dimmer switch, this approach aims to rid cells of problem proteins entirely. Earlier this year, the field got its best look yet at how well one common type of these drugs performs. Several have drugs in or near clinical testing.
Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.
Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational smallmolecule developed by Abbisko Therapeutics Co., In parallel, we are working to file a New Drug Application (NDA) to the U.S. Food and Drug Administration, with additional filings planned in other markets.”
Orforglipron ( LY-3502970 ) is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] 1] It was discovered by Chugai Pharmaceutical Co. 1] It was discovered by Chugai Pharmaceutical Co. then was licensed to Lilly in 2018. [1] April 17, 2025.
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] Journavx is the first drug to be approved in this new class of pain management medicines.
1] The US Food and Drug Administration granted the application for sebetralstat orphan drug designation. [4] 1] The US Food and Drug Administration granted the application for sebetralstat orphan drug designation. [4] Food and Drug Administration (FDA). Hz), 6.39 (1H, ddd, J=0.7, Hz), 7.75 (1H, ddd, J=0.7,
2] [3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [4] 1] [2] Adverse effects The US Food and Drug Administration prescription label for crinecerfont has a warning for acute adrenal insufficiency or adrenal crisis. [2] . : 321839-75-2 Molecular Weight 519.50 1] It is taken by mouth. [1]
As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. FAQs Q: What is the difference between a biosimilar and a generic drug? billion by 2025, growing at a CAGR of 34.2% from 2020 to 2025[1].
It is a smallmolecule delivered orally. [1] “Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine” Nature Communications. amcrasto@gmail.com NEW DRUG APPROVALS ONE TIME $10.00 amcrasto@gmail.com NEW DRUG APPROVALS ONE TIME $10.00 mmol) and DIPEA (1.19
Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes.
XH4D via Getty Images A group of private equity firms are pouring funding into PCI Pharma Services, betting the contract drug development and manufacturing organization’s business is poised to grow in the years ahead. PCI helps biopharmaceutical companies manufacture and package drug products used in clinical trials as well as commercially.
This observation, borne of accidental exposure, would eventually spur one of the first weight loss drug crazes — long before Ozempic and Mounjaro. In addition, upward of 20 wholesale drug firms are marketing the compound, which suggests that a considerable population is being medicated. Still, there wasn’t much the U.S.
Smallmoleculedrugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The smallmoleculesdrugs of today look nothing like the molecules of the 1970s.
49 Akilo-scale, chromatography-freesynthesisofhetrombopag has been reported by researchers at Jiangsu Hengrui Pharmaceutical in the Chinese-language patent literature (Scheme 12).50,51 Drugs 2021, 81, 1581−1585. (47) Developer Atridia; Jiangsu Hengrui Medicine Co. 50,51 Commercially available aniline 6.1 was coupledwith furoic acid (6.2)
1] Unlike other diabetes drugs, it is intended to increase insulin sensitivity. [2] 133 This first-in-class, smallmolecule,oral,glucokinaseactivator(GKA)wasfirst approved in ChinainSeptember2022foradultpatientswithT2DMasa monotherapy and in combination with metformin (an antidiabetic medication).134 Drugs 2022, 82, 1745−1750.
Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional smallmoleculedrug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel smallmolecule to target autoimmune disease.
Metabolism of 2022 FDA approved smallmoleculedrugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 smallmolecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism.
The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.
By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new smallmolecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-moleculedrug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.
1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional smallmolecules. Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. How does TPD work?
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle.
Between 2000 and 2020, approximately 30 percent of the newly introduced smallmoleculedrugs were derived from natural products. In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature. Why focus on natural products and phytochemicals?
Claud — Last week, FDA revised one of its two guidances relating to nitrosamines, Control of Nitrosamine Impurities in Human Drugs. Nitrosamines are impurities that can form during drug manufacturing and are considered potentially potent carcinogens. It’s these varied scenarios that give quality managers nightmares.
Dian Su’s journey from chemistry and proteomics to the DMPK of drug conjugates Following a different path comes naturally to Dian Su, Senior Director of DMPK at Bicycle Therapeutics. Dian eventually made her way to Shanghai, where she encountered a much bigger world while earning degrees in pharmaceutical engineering and medicinal chemistry.
One of our drug candidates at Samara activates Transient Receptor Potential Mucolipin 1 (TRPLM1), a protein that’s at the centre of the degradative machinery that’s so key to autophagy. 5 This drug candidate is progressing towards the clinic, with phase 1 trials due to start within 18 months.
Technologies for the rapid and efficient testing of smallmolecules and biologics have greatly accelerated drug discovery. However, many pharmaceutically relelvant targets remain ‘undruggable’. Impact of DNA-Encoded Chemical Library Technology on Drug Discovery. DNA-encoded chemical libraries. 2022 Jan 17;2(1).
In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. A big part of the puzzle is selectivity—the ability of a drug to zero in on specific biological molecules without affecting others.
A new lawsuit citing drug patent 7,795,312 has been filed. The smallmoleculedrug covered by this patent is AMITIZA. Takeda Pharmaceutical Company… The post New patent lawsuit: Walgreen CO v. See more details at Walgreen CO v.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content